WAVE — Waverley Pharma Share Price
0.000.00%
Last trade - 00:00- CA$0.81m
- CA$3.64m
- CA$0.48m
- 11
- 40
- 32
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -181.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 1.38 | 1.75 | 1.25 | 0.41 | 0.48 | n/a | n/a | -16.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 24th, 2017
- Public Since
- April 27th, 2017
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 54,000,000
- Address
- 4-1250 Waverley Street, WINNIPEG, R3T 6C6
- Web
- https://www.waverleypharma.com/
- Phone
- +1 2049287907
- Auditors
- Ernst & Young LLP
Upcoming Events for WAVE
Q3 2025 Waverley Pharma Inc Earnings Release
Similar to WAVE
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
MustGrow Biologics
TSX Venture Exchange
FAQ
What is the Waverley Pharma share price?
As of Today at 24:03 UTC, shares in Waverley Pharma are trading at CA$0.02. This share price information is delayed by 15 minutes.
How has the Waverley Pharma share price performed this year?
Shares in Waverley Pharma last closed at CA$0.02 and the price had moved by -25% over the past 365 days. In terms of relative price strength the Waverley Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -38.04% over the past year.
What are the analyst and broker recommendations for Waverley Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Waverley Pharma dividend yield?
Waverley Pharma does not currently pay a dividend.
Does Waverley Pharma pay a dividend?
Waverley Pharma does not currently pay a dividend.
When does Waverley Pharma next pay dividends?
Waverley Pharma does not currently pay a dividend.
How do I buy Waverley Pharma shares?
To buy shares in Waverley Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Waverley Pharma?
As of the previous close price of CA$0.02, shares in Waverley Pharma had a market capitalisation of CA$0.81m.
Where are Waverley Pharma shares listed?
Here are the trading details for Waverley Pharma:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: WAVE
What kind of share is Waverley Pharma?
Based on an overall assessment of its quality, value and momentum Waverley Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Waverley Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Waverley Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Waverley Pharma. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +37.87%.
As of the last closing price of CA$0.02, shares in Waverley Pharma were trading -51.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Waverley Pharma PE Ratio?
The Waverley Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Waverley Pharma?
Waverley Pharma's management team is headed by:
- Albert Friesen - CHM
- Larry Thiessen - PRE
- Haaris Uddin - CFO
- P. Marcus Enns - IND
- Hellen Siwanowicz - IND